Buy Senores Pharmaceuticals ltd for the Target Rs.960 by Choice Broking Ltd
Tariff-shielded, High Quality, Niche Generics Play
We believe SENORES is well-positioned for strong growth, led by 70 ANDA approvals, 75% complex generic filings, and high-margin controlled substances and government contracts. Growth will be further augmented by ANDA acquisitions from peers, such as DRRD and Teva, alongside scale-up in emerging markets where ~300 additional product approvals are expected over the next 15–18 months. The company remains insulated from tariff risks, with regulated markets served solely from its FDA-approved US facility, unlike peers reliant on India based exports. Margin expansion is expected to be driven by operating leverage from sterile injectables capex and backward integration through API sourcing.
Outlook
We believe SENORES is at an inflection point, supported by its differentiated pipeline and strong manufacturing base. We expect Revenue/EBITDA/PAT to deliver a CAGR of 27.9%/36.7%/41.2% over FY25–28E
For Detailed Report With Disclaimer Visit. https://choicebroking.in/disclaimer
SEBI Registration no.: INZ 000160131
